Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20314952 | 0.81 | CHRNB2 (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20334582 | 0.81 | KMT2A (0.38) | MEN1KMT2ATSHR | |
| SCHEMBL24337249 | 0.80 | MMP3 (0.31) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20314902 | 0.80 | CHRNB2 (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20314961 | 0.79 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20314934 | 0.79 | CTSK (0.34) | MEN1KMT2ATSHR | |
| SCHEMBL21741220 | 0.78 | POLB (0.37) | MEN1KMT2ATSHR | |
| SCHEMBL19010113 | 0.77 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15783542 | 0.77 | PIK3CD (0.43) | — | |
| SCHEMBL20711779 | 0.77 | EGFR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-02 | — | — | US | disclosed |
| EP-4001269-A1 | BENZOISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | ERASCA, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| WO-2018119183-A2 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | SDHB, CCNI, SDHA | MEN1 963/4885KMT2A 2767/4885TSHR 2992/4885 |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | MEN1 296/4885KMT2A 2069/4885TSHR 4359/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MEN1 296/4885KMT2A 2069/4885TSHR 4359/4885 |
| US-20220168280-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MEN1 296/4885KMT2A 2069/4885TSHR 4359/4885 |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MEN1 296/4885KMT2A 2069/4885TSHR 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.